There are limited established treatment options for ccRCC patients, including surgical resection, VEGF pathway inhibitors, and high-dose interleukin-2 (IL-2), although novel immunotherapies will likely join this list soon. Here, IL2 is linked to nonpapillary renal cell carcinoma.